Immunomodulatory drug and corticosteroid

This page covers all Immunomodulatory drug and corticosteroid drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Ubiquitin-proteasome pathway.

Targets

Ubiquitin-proteasome pathway

Phase 2 pipeline (1)

• Lenalidomide-Dexamethasone-DLI · Ciusss de L'Est de l'Île de Montréal · Oncology
  Lenalidomide is an immunomodulatory drug that targets the ubiquitin-proteasome pathway, and Dexamethasone is a corticosteroid that modulates the immune response. DLI (Donor Lymphocyte Infusion) is a form of immunotherapy that involves infusing donor lymphocytes to treat hematologic malignancies.

Patent intelligence

• immunomodulatory drug and corticosteroid patent landscape — aggregated cliff calendar, attackable patents, originator estates